Metagenomi Inc. is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox. Metagenomi Inc. is based in EMERYVILLE, Calif.
| Revenue (Most Recent Fiscal Year) | $52.29M |
| Net Income (Most Recent Fiscal Year) | $-78.06M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.47 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.31 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -184.18% |
| Net Margin (Trailing 12 Months) | -172.21% |
| Return on Equity (Trailing 12 Months) | -31.21% |
| Return on Assets (Trailing 12 Months) | -22.21% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.85 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.85 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.69 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.68 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.30 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.11 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 37.38M |
| Free Float | -- |
| Market Capitalization | $66.54M |
| Average Volume (Last 20 Days) | 0.28M |
| Beta (Past 60 Months) | -0.65 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |